• news.cision.com/
  • Attana/
  • Attana strengthens the operational team with four new employees, including a Chief Research Officer

Attana strengthens the operational team with four new employees, including a Chief Research Officer

Report this content

Attana can today announce that the company, after a recruitment process with a high number of applicants, has recruited four new employees: a Chief Research Officer, two Application Specialists and a Service Technician. The new employees all have an international background and extensive experience from Big Pharma and biotech.

The two Application Specialists and the Service Technician have a wide experience from working with drug development and contract research. These three join Attana to strengthen the company's capacity and the company’s offering in contract research and instrument sales. In addition, Attana has appointed a new role and recruited a Chief Research Officer with extensive experience from Big Pharma; most recently as a late-stage development specialist at one of the major pharmaceutical companies. Going forward, this person will be responsible for Attana's product development and to ensure that the commercial potential of the company's core technology is fully realized. The new employees join continuously during the spring and all are on site at Attana by the end of the summer.

CEO, Teodor Aastrup, comments:
“The fact that we have had so many qualified applicants is a sign that we are heading in the right direction and that there is great interest in us as a company. We have seen a potential to increase our capacity by adding more experience in the direct operations to meet the increasing demand for our products and services, and a strengthened team is therefore very timely. I am proud that we have succeeded in recruiting such well-qualified employees and these will complement our existing team very well.”

For more information, please contact:

Teodor Aastrup, CEO
+46 (0)8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com


Documents & Links